Results of concurrent radiotherapy and immunotherapy in recurrent and metastatic head and neck cancer: A single-center experience.


Journal

Oral oncology
ISSN: 1879-0593
Titre abrégé: Oral Oncol
Pays: England
ID NLM: 9709118

Informations de publication

Date de publication:
01 2022
Historique:
received: 17 11 2021
revised: 24 11 2021
accepted: 27 11 2021
pubmed: 10 12 2021
medline: 12 4 2022
entrez: 9 12 2021
Statut: ppublish

Résumé

In metastatic and recurrent head and neck cancer (M/R HN-SCC), the median survival is less than a year and locoregional recurrence is the main cause of death. Our aim was to evaluate the results of concurrent stereotactic body radiotherapy (SBRT) and immunotherapy (ICI) in these patients. Fifteen patients diagnosed with M/R HN-SCC were evaluated retrospectively. All patients received SBRT (3x8 Gy) to all recurrent and metastatic foci with concurrent ICI. Six months overall survival (OS) rates and progression-free survival (PFS) rates were 93% and 86%, respectively. Local control (LC) rate in the site of SBRT was 96%. Higher survival and LC rates were achieved with lower doses of radiotherapy with the synergistic effect of SBRT and ICI. Concurrent ICI and SBRT was feasible with excellent LC.

Identifiants

pubmed: 34883400
pii: S1368-8375(21)00765-X
doi: 10.1016/j.oraloncology.2021.105658
pii:
doi:

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

105658

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Auteurs

Sezin Yuce Sari (SY)

Department of Radiation Oncology, Hacettepe University, Faculty of Medicine, Ankara, Turkey. Electronic address: sezin_yuce@hotmail.com.

Melek Tugce Yilmaz (MT)

Department of Radiation Oncology, Hacettepe University, Faculty of Medicine, Ankara, Turkey. Electronic address: mlktgcylmz@gmail.com.

Burak Yasin Aktas (BY)

Department of Medical Oncology, Afyonkarahisar State Hospital, Afyonkarahisar, Turkey. Electronic address: byaktas@hacettepe.edu.tr.

Sercan Aksoy (S)

Department of Medical Oncology, Hacettepe University, Faculty of Medicine, Ankara, Turkey. Electronic address: saksoy@hacettepe.edu.tr.

Ibrahim Gullu (I)

Department of Medical Oncology, Hacettepe University, Faculty of Medicine, Ankara, Turkey. Electronic address: ibrahimhalil.gullu@hacettepe.edu.tr.

Mustafa Cengiz (M)

Department of Radiation Oncology, Hacettepe University, Faculty of Medicine, Ankara, Turkey. Electronic address: mcengiz@hacettepe.edu.tr.

Gokhan Ozyigit (G)

Department of Radiation Oncology, Hacettepe University, Faculty of Medicine, Ankara, Turkey. Electronic address: gozyigit@hacettepe.edu.tr.

Gozde Yazici (G)

Department of Radiation Oncology, Hacettepe University, Faculty of Medicine, Ankara, Turkey. Electronic address: yazicig@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH